{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:37:32Z","timestamp":1777955852182,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Plan Project of Sichuan Province","award":["2021YJ0155"],"award-info":[{"award-number":["2021YJ0155"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13123-x","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:27:16Z","timestamp":1774456036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of albuvirtide and dolutegravir for HIV postexposure prophylaxis in men who have sex with men: a prospective non-randomized cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Huanxia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongtong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"13123_CR1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12879-016-1904-5","volume":"16","author":"S Tang","year":"2016","unstructured":"Tang S, Tang W, Meyers K, Chan P, Chen Z, Tucker JD. HIV epidemiology and responses among men who have sex with men and transgender individuals in China: a scoping review. BMC Infect Dis. 2016;16(1):588.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"13123_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10461-020-02972-5","volume":"25","author":"CH Logie","year":"2021","unstructured":"Logie CH, Wang Y, Lalor P, Williams D, Levermore K. Pre and Post-exposure Prophylaxis Awareness and Acceptability Among Sex Workers in Jamaica: A Cross-Sectional Study. AIDS Behav. 2021;25(2):330\u201343.","journal-title":"AIDS Behav"},{"issue":"1","key":"13123_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12879-025-10795-9","volume":"25","author":"R Su","year":"2025","unstructured":"Su R, Liu Y, Li P, Ge L, Liao M, Fu Y, et al. Usage of post-exposure prophylaxis and its impact on risk behaviors among men who have sex with men in Qingdao, China. BMC Infect Dis. 2025;25(1):421.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"13123_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/QAD.0000000000001447","volume":"31","author":"JW McAllister","year":"2017","unstructured":"McAllister JW, Towns JM, McNulty A, Pierce AB, Foster R, Richardson R, Carr A. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. AIDS. 2017;31(9):1291\u20135.","journal-title":"AIDS"},{"issue":"6","key":"13123_CR5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/jac\/dkx062","volume":"72","author":"A Milinkovic","year":"2017","unstructured":"Milinkovic A, Benn P, Arenas-Pinto A, Brima N, Copas A, Clarke A, et al. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra(R) in combination with Truvada(R) for HIV post-exposure prophylaxis (MiPEP Trial). J Antimicrob Chemother. 2017;72(6):1760\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"13123_CR6","doi-asserted-by":"publisher","first-page":"2288309","DOI":"10.1080\/07853890.2023.2288309","volume":"55","author":"S Liu","year":"2023","unstructured":"Liu S, Yuan D, Zhou Y, Fu G, Wang B. Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies. Ann Med. 2023;55(2):2288309.","journal-title":"Ann Med"},{"issue":"05","key":"13123_CR7","first-page":"499","volume":"29","author":"F Zhao","year":"2023","unstructured":"Zhao F, Li Z, Zhao H, Sun L, Zhao Q, He S, et al. Expert consensus on dual simplified therapy for HIV antiviral therapy 2023. Zhongguo Aizibing Xingbing. 2023;29(05):499\u2013508.","journal-title":"Zhongguo Aizibing Xingbing"},{"issue":"45","key":"13123_CR8","doi-asserted-by":"publisher","first-page":"e35344","DOI":"10.1097\/MD.0000000000035344","volume":"102","author":"H Liu","year":"2023","unstructured":"Liu H, He S, Yang T, Lu C, Yao Y, Zhou R, et al. Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV\/AIDS. Med (Baltim). 2023;102(45):e35344.","journal-title":"Med (Baltim)"},{"issue":"12","key":"13123_CR9","first-page":"1106","volume":"60","author":"HC Aids","year":"2021","unstructured":"Aids HC, Professional Group SoIDCMA. Chinese Center for Disease C, Prevention. [Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)]. Zhonghua nei ke za zhi. 2021;60(12):1106\u201328.","journal-title":"Zhonghua nei ke za zhi"},{"key":"13123_CR10","unstructured":"China CDC. AIDS Prevention and control technical guidelines for HIV Post-exposure Prophylaxis (trial). [EB\/OL]. 2020 Oct [cited 2021 Sep 20]. Available from: http:\/\/ncaids.chinacdc.cn\/tzgggd\/202011\/W02020111680222550750.pdf."},{"key":"13123_CR11","unstructured":"Fu Y, Gan L, Song Y, Song C, Sun F, Guo L, Long H. Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study. AIDS. 2022. 10.1097."},{"key":"13123_CR12","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [EB\/OL]. 2017 Nov 27 [cited 2021 Sep 20]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_."},{"issue":"4","key":"13123_CR13","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","volume":"10","author":"J Nie","year":"2021","unstructured":"Nie J, Sun F, He X, Liu J, Wang M, Li C, et al. Tolerability and adherence of antiretroviral regimens containing long-acting fusion inhibitor albuvirtide for HIV post-exposure prophylaxis: a cohort study in China. Infect Dis Therapy. 2021;10(4):2611\u201323.","journal-title":"Infect Dis Therapy"},{"issue":"11","key":"13123_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/hiv.13542","volume":"24","author":"J Ambrosioni","year":"2023","unstructured":"Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, et al. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med. 2023;24(11):1126\u201336.","journal-title":"HIV Med"},{"issue":"24","key":"13123_CR15","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","volume":"133","author":"B Su","year":"2020","unstructured":"Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919\u201327.","journal-title":"Chin Med J (Engl)"},{"issue":"29","key":"13123_CR16","doi-asserted-by":"publisher","first-page":"eadg5953","DOI":"10.1126\/sciadv.adg5953","volume":"9","author":"M Li","year":"2023","unstructured":"Li M, Oliveira Passos D, Shan Z, Smith SJ, Sun Q, Biswas A, et al. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants. Sci Adv. 2023;9(29):eadg5953.","journal-title":"Sci Adv"},{"issue":"5","key":"13123_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/apc.2019.0313","volume":"34","author":"Z Wang","year":"2020","unstructured":"Wang Z, Yuan T, Fan S, Qian HZ, Li P, Zhan Y, et al. HIV Nonoccupational Postexposure Prophylaxis Among Men Who Have Sex with Men: A Systematic Review and Meta-Analysis of Global Data. AIDS Patient Care STDs. 2020;34(5):193\u2013204.","journal-title":"AIDS Patient Care STDs"},{"key":"13123_CR18","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for HIV post-exposure prophylaxis. Geneva: World Health Organization \u00a9 World Health Organization 2024.; 2024."},{"issue":"8","key":"13123_CR19","doi-asserted-by":"publisher","first-page":"ofad374","DOI":"10.1093\/ofid\/ofad374","volume":"10","author":"A Inciarte","year":"2023","unstructured":"Inciarte A, Ugarte A, Martinez-Rebollar M, Torres B, Fernandez E, Berrocal L, et al. Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP). Open Forum Infect Dis. 2023;10(8):ofad374.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"13123_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s12879-023-08544-x","volume":"23","author":"I Devred","year":"2023","unstructured":"Devred I, Kayembe K, Valin N, Rougier H, Shinga BW, Lambert-Niclot S, et al. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV. BMC Infect Dis. 2023;23(1):578.","journal-title":"BMC Infect Dis"},{"key":"13123_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","volume":"13","author":"H Zhang","year":"2016","unstructured":"Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients. AIDS Res therapy. 2016;13:8.","journal-title":"AIDS Res therapy"},{"issue":"1","key":"13123_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/QAI.0000000000002912","volume":"90","author":"KH Mayer","year":"2022","unstructured":"Mayer KH, Gelman M, Holmes J, Kraft J, Melbourne K, Mimiaga MJ. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. J Acquir Immune Defic Syndr. 2022;90(1):27\u201332.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"13123_CR23","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/cid\/civ511","volume":"61","author":"R Foster","year":"2015","unstructured":"Foster R, McAllister J, Read TR, Pierce AB, Richardson R, McNulty A, Carr A. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men. Clin Infect diseases: official publication Infect Dis Soc Am. 2015;61(8):1336\u201341.","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"10","key":"13123_CR24","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1093\/jac\/dkx246","volume":"72","author":"A Inciarte","year":"2017","unstructured":"Inciarte A, Leal L, Gonz\u00e1lez E, Le\u00f3n A, Lucero C, Mallolas J, et al. Tenofovir disoproxil fumarate\/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. J Antimicrob Chemother. 2017;72(10):2857\u201361.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"13123_CR25","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s40121-021-00540-5","volume":"10","author":"J Nie","year":"2021","unstructured":"Nie J, Sun F, He X, Liu J, Wang M, Li C, et al. Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China. Infect Dis Ther. 2021;10(4):2611\u201323.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"13123_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/10600280221102532","volume":"57","author":"SH Durham","year":"2023","unstructured":"Durham SH, Milam A, Waer D, Chahine EB. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. Ann Pharmacother. 2023;57(3):306\u201316.","journal-title":"Ann Pharmacother"},{"key":"13123_CR27","doi-asserted-by":"publisher","first-page":"e46767","DOI":"10.2196\/46767","volume":"9","author":"W Wang","year":"2023","unstructured":"Wang W, Zhao S, Wu Y, Duan W, Li S, Li Z, et al. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis. JMIR Public Health Surveill. 2023;9:e46767.","journal-title":"JMIR Public Health Surveill"},{"issue":"7","key":"13123_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/QAD.0000000000004130","volume":"39","author":"X Xie","year":"2025","unstructured":"Xie X, Fu Y, Gan L, Yang X, Song Y, Song C, et al. Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study. AIDS. 2025;39(7):857\u201362.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13123-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:22:54Z","timestamp":1777936974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13123-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13123"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13123-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the ethics committee of Chengdu Public Health Clinical Medical Center (PK-K2020-60-01), and all procedures were conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"891"}}